Altan Pharma Announces the Launch of Linezolid 2mg/ml Solution for Infusion in Spain
Altan Pharma Limited (“Altan”), an Irish specialty pharmaceutical company today announced that it has launched linezolid 2mg/ml solution for infusion for the treatment of community acquired pneumonia and nosocomial pneumonia in Spain through its Spanish subsidiary Genéricos Españoles Laboratorio, S.A.U.
According to IMS, the market for Linezolid solution for infusion in Spain was roughly €23 million in 2015.
About Linezolid Solution for Infusion
Linezolid is indicated for the treatment of community acquired pneumonia and nosocomial pneumonia when known or suspected to be caused by susceptible gram positive bacteria. It is also indicated for the treatment of complicated skin and soft tissue infections only when microbiological testing has established that the infection is known to be caused by susceptible Gram positive bacteria. Linezolid should only be initiated in a hospital setting.
Please see the package insert for indications, complete side effect profile and prescribing information.
About Altan Pharma Ltd.
Altan Pharma Ltd. is a privately held, specialty pharmaceutical company that develops, manufactures and commercialises injectable drugs for the hospital and other provider segments. Altan has an international distribution network covering many European, Latin American and Asian markets. The company is highly focused on building its pipeline of injectable drugs and expanding its commercial presence to new markets through both organic and inorganic means.
For more information visit www.altanpharma.com
Altan Media Relations
Tel: +353 (1) 908 1280
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
BOEHRINGER-INGELHEIM26.9.2018 10:02 | pressemeddelelse
Global survey reveals that physicians need more information to assess the impact of treatment sequencing on patient survival in EGFR mutation-positive NSCLC
SOFTATHOME26.9.2018 09:02 | pressemeddelelse
SoftAtHome Invests in Quality of Experience for Fixed-Mobile Convergence by Acquiring V3D, Leader in Telecom Data Analytics
EASY-VISUAL26.9.2018 09:02 | pressemeddelelse
Easy Visual Launches App For Targeted Advertising Reach Through Smartphones
CA-TELEFLEX26.9.2018 08:07 | pressemeddelelse
NeoTract Announces Results from Five Real-World Studies Reaffirming Efficacy and Safety of UroLift® System Treatment for Enlarged Prostate
CA-NEOTRACT26.9.2018 08:07 | pressemeddelelse
NeoTract Announces Results from Two Studies Demonstrating Transformative Benefits of the UroLift® System for BPH Care
OLIVER-WYMAN26.9.2018 08:02 | pressemeddelelse
Oliver Wyman Supports Inclusion Initiative in the Nordics
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum